Sino Biopharmaceutical Limited (HKG:1177)

Hong Kong flag Hong Kong · Delayed Price · Currency is HKD
7.98
+0.03 (0.38%)
Sep 29, 2025, 11:45 AM HKT
132.65%
Market Cap 142.12B
Revenue (ttm) 33.49B
Net Income (ttm) 4.24B
Shares Out 17.88B
EPS (ttm) 0.23
PE Ratio 33.70
Forward PE 28.62
Dividend 0.10 (1.26%)
Ex-Dividend Date Aug 29, 2025
Volume 35,448,666
Average Volume 143,178,220
Open 8.03
Previous Close 7.95
Day's Range 7.84 - 8.08
52-Week Range 2.67 - 9.12
Beta 0.71
RSI 44.71
Earnings Date Nov 17, 2025

About Sino Biopharmaceutical

Sino Biopharmaceutical Limited, an investment holding company, operates as a research and development pharmaceutical conglomerate in the People’s Republic of China. It operates through three segments: Modernised Chinese Medicines and Chemical Medicines, Investment, and Others. The company offers oncology medicines, including anlotinib hydrochloride capsules under Focus V brand, penpulimab injection under Annike brand, efbemalenograstin alfa injection under Yilishu brand, benmelstobart injection under Andewei brand, unecritinib fumarate capsules... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2000
Employees 24,379
Stock Exchange Hong Kong Stock Exchange
Ticker Symbol 1177
Full Company Profile

Financial Performance

In 2024, Sino Biopharmaceutical's revenue was 28.87 billion, an increase of 10.18% compared to the previous year's 26.20 billion. Earnings were 3.50 billion, an increase of 50.08%.

Financial numbers in CNY Financial Statements

News

Hong Kong stocks slip from 4-year high amid fears of US sanctions on drug makers

A rally that sent Hong Kong stocks to the highest level in four years took a breather, as Chinese drug makers tumbled amid fears that the Trump administration would impose fresh curbs on medicine expo...

18 days ago - South China Morning Post

Hong Kong stocks waver on China’s mixed economic data

Hong Kong stocks swung between gains and losses after China reported a mixed bag of economic data from May. The Hang Seng Index rose 0.1 per cent to 23,907.52 as of 10.23am local time. The Hang Seng T...

3 months ago - South China Morning Post

Hong Kong stocks fall slightly on rising geopolitical tensions

Hong Kong stocks dropped on Friday as rising geopolitical tensions dimmed investors’ appetite for risk assets. The Hang Seng Index fell 0.4 per cent to 23,950.45 at 10.10am local time, though it was s...

3 months ago - South China Morning Post

Sino Biopharmaceutical Limited goes ex-dividend tomorrow

Sino Biopharmaceutical Limited (SBHMY) declares $0.0653/share quarterly dividend, payable Oct. 18 for shareholders of record Sept. 12.

1 year ago - Seeking Alpha

Sino Biopharmaceutical to divest 67% stake in unit CP Qingdao for $253 mln

Hong Kong-listed Sino Biopharmaceutical will sell a 67% stake in unit CP Pharmaceutical (Qingdao) for 1.82 billion yuan ($253.28 million) to entities controlled by state-owned Guoxin Group, the compan...

1 year ago - Reuters

China's health-care sector may be next to face regulatory crackdown, says economist

Dan Wang of Hang Seng Bank (China) says China's public health-care system is still expensive for ordinary people. The country's regulatory reform will be nationwide and have an international impact, s...

4 years ago - CNBC International TV

Chinese Company Gets FDA Approval For Drug To Fight Chemotherapy Nausea

Cancer killed far more people around the world than Covid-19 in 2020

4 years ago - Forbes

Week In Review: JD Health Raises $3.5 Billion In Hong Kong IPO, Climbs 56% On First Day

JD Health of Guangzhou, the online health-care arm of China e-commerce giant JD.com, completed a $3.5 billion Hong Kong IPO and rose 56% in its first trading session. Beijing's Sinovac Biotech reporte...

5 years ago - Seeking Alpha